Cargando…

Tumour-derived extracellular vesicle based vaccines for melanoma treatment

The interest of extracellular vesicles (EVs) in cancer immunotherapy is increasing every day. EVs are lipid bilayer vesicles released by most cells, which contain the molecular signature of their parent cell. Melanoma-derived EVs present antigens specific to this aggressive type of cancer, but they...

Descripción completa

Detalles Bibliográficos
Autores principales: Gonzalez-Melero, Lorena, Hernandez, Rosa Maria, Santos-Vizcaino, Edorta, Igartua, Manoli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10102154/
https://www.ncbi.nlm.nih.gov/pubmed/37022605
http://dx.doi.org/10.1007/s13346-023-01328-5
_version_ 1785025641643507712
author Gonzalez-Melero, Lorena
Hernandez, Rosa Maria
Santos-Vizcaino, Edorta
Igartua, Manoli
author_facet Gonzalez-Melero, Lorena
Hernandez, Rosa Maria
Santos-Vizcaino, Edorta
Igartua, Manoli
author_sort Gonzalez-Melero, Lorena
collection PubMed
description The interest of extracellular vesicles (EVs) in cancer immunotherapy is increasing every day. EVs are lipid bilayer vesicles released by most cells, which contain the molecular signature of their parent cell. Melanoma-derived EVs present antigens specific to this aggressive type of cancer, but they also exert immunomodulatory and pro-metastatic activity. Until now, most reviews focus on the immunoevasive characteristics of tumour-derived EVs, but do not help to overcome the issues related to them. In this review, we describe isolation methods of EVs from melanoma patients and most interesting markers to oversee their effect if they are used as antigen carriers. We also discuss the methods developed so far to overcome the lack of immunogenicity of melanoma-derived EVs, which includes EV modification or adjuvant co-administration. In summary, we conclude that EVs can be an interesting antigen source for immunotherapy development once EV obtaining is optimised and the understanding of the mechanisms behind their multiple effects is further understood. GRAPHICAL ABSTRACT: [Image: see text]
format Online
Article
Text
id pubmed-10102154
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-101021542023-04-15 Tumour-derived extracellular vesicle based vaccines for melanoma treatment Gonzalez-Melero, Lorena Hernandez, Rosa Maria Santos-Vizcaino, Edorta Igartua, Manoli Drug Deliv Transl Res Original Article The interest of extracellular vesicles (EVs) in cancer immunotherapy is increasing every day. EVs are lipid bilayer vesicles released by most cells, which contain the molecular signature of their parent cell. Melanoma-derived EVs present antigens specific to this aggressive type of cancer, but they also exert immunomodulatory and pro-metastatic activity. Until now, most reviews focus on the immunoevasive characteristics of tumour-derived EVs, but do not help to overcome the issues related to them. In this review, we describe isolation methods of EVs from melanoma patients and most interesting markers to oversee their effect if they are used as antigen carriers. We also discuss the methods developed so far to overcome the lack of immunogenicity of melanoma-derived EVs, which includes EV modification or adjuvant co-administration. In summary, we conclude that EVs can be an interesting antigen source for immunotherapy development once EV obtaining is optimised and the understanding of the mechanisms behind their multiple effects is further understood. GRAPHICAL ABSTRACT: [Image: see text] Springer US 2023-04-06 2023 /pmc/articles/PMC10102154/ /pubmed/37022605 http://dx.doi.org/10.1007/s13346-023-01328-5 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Gonzalez-Melero, Lorena
Hernandez, Rosa Maria
Santos-Vizcaino, Edorta
Igartua, Manoli
Tumour-derived extracellular vesicle based vaccines for melanoma treatment
title Tumour-derived extracellular vesicle based vaccines for melanoma treatment
title_full Tumour-derived extracellular vesicle based vaccines for melanoma treatment
title_fullStr Tumour-derived extracellular vesicle based vaccines for melanoma treatment
title_full_unstemmed Tumour-derived extracellular vesicle based vaccines for melanoma treatment
title_short Tumour-derived extracellular vesicle based vaccines for melanoma treatment
title_sort tumour-derived extracellular vesicle based vaccines for melanoma treatment
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10102154/
https://www.ncbi.nlm.nih.gov/pubmed/37022605
http://dx.doi.org/10.1007/s13346-023-01328-5
work_keys_str_mv AT gonzalezmelerolorena tumourderivedextracellularvesiclebasedvaccinesformelanomatreatment
AT hernandezrosamaria tumourderivedextracellularvesiclebasedvaccinesformelanomatreatment
AT santosvizcainoedorta tumourderivedextracellularvesiclebasedvaccinesformelanomatreatment
AT igartuamanoli tumourderivedextracellularvesiclebasedvaccinesformelanomatreatment